$荣昌生物(SH688331)$ 出自2026年2月3日 发布的 $辉瑞(PFE)$ 2025年第四季度及全年财报新闻稿（Earnings Release）及其附带的财务报告，涉及disitamab vedotin 的原文如下：

The amount for the fourth quarter and full-year 2025 includes intangible asset impairment charges due to changes in development plans and updated long-range commercial forecasts, primarily composed of the following: (i) $3.6 billion in impairments of in-process research and developmen